

Anthony D Kelleher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2398866/publications.pdf>

Version: 2024-02-01

186
papers

10,883
citations

36271

51
h-index

38368

95
g-index

199
all docs

199
docs citations

199
times ranked

13560
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with treated indolent lymphomas immunized with <scp>BNT162b2</scp> have reduced anti- ϵ spike neutralizing <scp>IgG</scp> to <scp>SARS-CoV-2</scp> variants, but preserved antigen-specific α 2.0 T cell responses. American Journal of Hematology, 2023, 98, 131-139.		9
2	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Reports, 2022, 38, 110345.	2.9	30
3	Nanoscale probing and imaging of HIV-1 RNA in cells with a chimeric LNA-DNA sensor. Nanoscale, 2022, , .	2.8	0
4	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, 2022, 23, 210-216.	7.0	486
5	Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. iScience, 2022, 25, 103656.	1.9	8
6	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. Journal of Clinical Investigation, 2022, 132, .	3.9	52
7	Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. International Journal of Molecular Sciences, 2022, 23, 2408.	1.8	13
8	Navigating the complexity of chronic HIV-1 associated immune dysregulation. Current Opinion in Immunology, 2022, 76, 102186.	2.4	7
9	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	5.9	32
10	Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection. Pharmaceutics, 2022, 14, 1352.	2.0	1
11	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 1141-1146.	2.9	2
12	CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. International Journal of Molecular Sciences, 2021, 22, 912.	1.8	2
13	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. MAbs, 2021, 13, 1922134.	2.6	22
14	SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses, 2021, 13, 247.	1.5	28
15	Pacific Eclipse: Before the corona dawn. Vaccine, 2021, , .	1.7	0
16	Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Medical Journal of Australia, 2021, 214, 279-280.	0.8	41
17	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66
18	Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men. HIV Medicine, 2021, 22, 605-616.	1.0	9

#	ARTICLE	IF	CITATIONS
19	The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowatâ€Wilson Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5324.	1.8	4
20	Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 688886.	2.2	9
21	Characteristics of Agreements to have Condomless Anal Intercourse in the Presence of an Undetectable Viral Load Among HIV Serodiscordant Male Couples in Australia, Brazil and Thailand. <i>AIDS and Behavior</i> , 2021, 25, 3944-3954.	1.4	2
22	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. <i>PLoS Medicine</i> , 2021, 18, e1003656.	3.9	109
23	Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. <i>EBioMedicine</i> , 2021, 70, 103518.	2.7	3
24	Evolution of HIV-1 Surveillance Drug Resistance Mutations Over 10 Years in New South Wales, Australia. <i>AIDS Research and Human Retroviruses</i> , 2021, , .	0.5	2
25	Subtypeâ€specific differences in transmission cluster dynamics of HIVâ€1 B and CRF01_AE in New South Wales, Australia. <i>Journal of the International AIDS Society</i> , 2021, 24, e25655.	1.2	7
26	Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort. <i>ERJ Open Research</i> , 2021, 7, 00384-2021.	1.1	17
27	Human MAIT cells respond to and suppress HIV-1. <i>ELife</i> , 2021, 10, .	2.8	14
28	Tfh Cells in Health and Immunity: Potential Targets for Systems Biology Approaches to Vaccination. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8524.	1.8	18
29	Block and Lock HIV Cure Strategies to Control the Latent Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 424.	1.8	42
30	Increased HIV Subtype Diversity Reflecting Demographic Changes in the HIV Epidemic in New South Wales, Australia. <i>Viruses</i> , 2020, 12, 1402.	1.5	4
31	RNAi therapeutics: an antiviral strategy for human infections. <i>Current Opinion in Pharmacology</i> , 2020, 54, 121-129.	1.7	16
32	High CD26 and Low CD94 Expression Identifies an IL-23 Responsive VÎ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile. <i>Cell Reports</i> , 2020, 31, 107773.	2.9	32
33	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. <i>Cell</i> , 2020, 180, 878-894.e19.	13.5	82
34	Circulating glutenâ€specific, but not CMVâ€specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire. <i>Clinical and Translational Immunology</i> , 2020, 9, e1096.	1.7	7
35	Mapping the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph nodes. <i>Aids</i> , 2020, 34, 833-848.	1.0	17
36	Proâ€inflammatory dopamineâ€2 receptorâ€specific T cells in paediatric movement and psychiatric disorders. <i>Clinical and Translational Immunology</i> , 2020, 9, e1229.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Impact of HIV-1 viremia or sexually transmitted infection on semen-derived anti-HIV-1 antibodies and the immunosuppressive capacity of seminal plasma. <i>European Journal of Immunology</i> , 2019, 49, 2255-2258.	1.6	1
38	Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers. <i>Frontiers in Immunology</i> , 2019, 10, 1844.	2.2	25
39	Limited Sustained Local Transmission of HIV-1 CRF01_AE in New South Wales, Australia. <i>Viruses</i> , 2019, 11, 482.	1.5	4
40	Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques. <i>Scientific Reports</i> , 2019, 9, 5661.	1.6	14
41	Strategies used by gay male HIV serodiscordant couples to reduce the risk of HIV transmission from anal intercourse in three countries. <i>Journal of the International AIDS Society</i> , 2019, 22, e25277.	1.2	15
42	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of <i>In Vitro</i> versus <i>In Vivo</i> Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	3
43	Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 $\Delta 32$ heterozygous and HLA-B57 genotype. <i>Journal of Virus Eradication</i> , 2019, 5, 73-83.	0.3	13
44	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
45	Functional cure of HIV: the scale of the challenge. <i>Nature Reviews Immunology</i> , 2019, 19, 45-54.	10.6	93
46	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
47	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	1.4	14
48	HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 112-120.	0.5	16
49	HIV Infection as a Model of Accelerated Immunosenescence. , 2019, , 1961-1989.		1
50	Possible clearance of transfusion-acquired /LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 $\Delta 32$ heterozygous and HLA-B57 genotype. <i>Journal of Virus Eradication</i> , 2019, 5, 73-83.	0.3	5
51	The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targets. <i>Journal of the International AIDS Society</i> , 2018, 21, e25109.	1.2	26
52	Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018, 38, 159-162.	2.0	3
53	Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. <i>Journal of Immunological Methods</i> , 2018, 457, 41-52.	0.6	51
54	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2018, 5, e553-e559.	2.1	19

#	ARTICLE	IF	CITATIONS
55	RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency. <i>Retrovirology</i> , 2018, 15, 67.	0.9	34
56	Influence of Population Immunosuppression and Past Vaccination on Smallpox Reemergence. <i>Emerging Infectious Diseases</i> , 2018, 24, 646-653.	2.0	25
57	HIV-1 subtype diversity, transmitted drug resistance and phylogenetics in Australia. <i>Future Virology</i> , 2018, 13, 575-584.	0.9	4
58	Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. <i>Lancet HIV</i> , 2018, 5, e438-e447.	2.1	337
59	Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. <i>Nature Communications</i> , 2018, 9, 3372.	5.8	88
60	Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 936-941.	0.5	7
61	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 328-337.	0.9	32
62	Single-cell profiling of lineage determining transcription factors in antigen-specific CD4 + T cells reveals unexpected complexity in recall responses during immune reconstitution. <i>Immunology and Cell Biology</i> , 2017, 95, 640-646.	1.0	6
63	Expanding role for type I Interferons in restricting HIV growth. <i>Immunology and Cell Biology</i> , 2017, 95, 417-418.	1.0	1
64	Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353.	0.9	12
65	Circulating gluten-specific FOXP3 + CD39 + regulatory T cells have impaired suppressive function in patients with celiac disease. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1592-1603.e8.	1.5	63
66	Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 648-657.	0.5	32
67	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	1.9	20
68	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , 2017, 7, 10934.	1.6	36
69	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. <i>Journal of Virology</i> , 2017, 91, .	1.5	59
70	Mechanism of Interferon-Stimulated Gene Induction in HIV-1-Infected Macrophages. <i>Journal of Virology</i> , 2017, 91, .	1.5	46
71	Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?. <i>Frontiers in Immunology</i> , 2017, 8, 19.	2.2	177
72	HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. <i>Frontiers in Immunology</i> , 2017, 8, 376.	2.2	26

#	ARTICLE	IF	CITATIONS
73	Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 495.	2.2	11
74	A national study of the molecular epidemiology of HIV-1 in Australia 2005â€“2012. <i>PLoS ONE</i> , 2017, 12, e0170601.	1.1	29
75	Differentiating founder and chronic HIV envelope sequences. <i>PLoS ONE</i> , 2017, 12, e0171572.	1.1	3
76	HIV dynamics linked to memory CD4+ T cell homeostasis. <i>PLoS ONE</i> , 2017, 12, e0186101.	1.1	11
77	CD4+ T Follicular Helper and IgA+ B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals. <i>Frontiers in Immunology</i> , 2016, 7, 438.	2.2	13
78	Achieving HIV-1 Control through RNA-Directed Gene Regulation. <i>Genes</i> , 2016, 7, 119.	1.0	10
79	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016, 30, 879-888.	1.0	9
80	Immune activation and immune aging in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 242-249.	1.5	66
81	Nuclear PKC- ζ facilitates rapid transcriptional responses in human memory CD4+ T cells <i>via</i> p65 and H2B phosphorylation. <i>Journal of Cell Science</i> , 2016, 129, 2448-61.	1.2	11
82	Maraviroc, as a Switch Option, in HIV-1â€“infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 122-132.	2.9	21
83	Computationally efficient multidimensional analysis of complex flow cytometry data using second order polynomial histograms. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 44-58.	1.1	10
84	Comment on “A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood” • <i>Journal of Immunology</i> , 2016, 197, 2557-2558.	0.4	3
85	The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. <i>Vaccine</i> , 2016, 34, 5251-5261.	1.7	28
86	The feasibility of incorporating Vpx into lentiviral gene therapy vectors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16066.	1.8	6
87	Control of early HIV-1 infection associates with plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibodies to HIV-1 p24. <i>Aids</i> , 2016, 30, 2757-2765.	1.0	16
88	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5â€“8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	2.1	21
89	Detecting Antigen-Specific T Cell Responses: From Bulk Populations to Single Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18878-18893.	1.8	28
90	The Role of PKC- ζ in CD4+ T Cells and HIV Infection: To the Nucleus and Back Again. <i>Frontiers in Immunology</i> , 2015, 6, 391.	2.2	8

#	ARTICLE	IF	CITATIONS
91	Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. <i>Frontiers in Immunology</i> , 2015, 6, 474.	2.2	21
92	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0139981.	1.1	45
93	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	2.1	92
94	Human Papillomavirus 16—Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions. <i>Journal of Infectious Diseases</i> , 2015, 211, 405-415.	1.9	29
95	MAIT cells are depleted early but retain functional cytokine expression in HIV infection. <i>Immunology and Cell Biology</i> , 2015, 93, 177-188.	1.0	90
96	Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. <i>Lancet HIV</i> , 2015, 2, e42-e51.	2.1	68
97	Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e222.	2.3	27
98	Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. <i>Aids</i> , 2015, 29, 911-919.	1.0	37
99	T Follicular Helper Cells Have Distinct Modes of Migration and Molecular Signatures in Naive and Memory Immune Responses. <i>Immunity</i> , 2015, 42, 704-718.	6.6	159
100	Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e261.	2.3	43
101	Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. <i>Nature Communications</i> , 2015, 6, 8495.	5.8	146
102	Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 529-538.	1.9	28
103	HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. <i>PLoS ONE</i> , 2015, 10, e0140978.	1.1	49
104	Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. <i>World Journal of Virology</i> , 2015, 4, 219.	1.3	16
105	Ratios of effector to central memory antigen-specific CD4 ⁺ T cells vary with antigen exposure in HIV+ patients. <i>Immunology and Cell Biology</i> , 2014, 92, 384-388.	1.0	10
106	HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 ⁺ T Cells during Antiretroviral Therapy. <i>Journal of Virology</i> , 2014, 88, 3516-3526.	1.5	76
107	The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. <i>BMC Public Health</i> , 2014, 14, 917.	1.2	39
108	MicroRNA modulation of key targets associated with T cell exhaustion in HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 464-471.	1.5	19

#	ARTICLE	IF	CITATIONS
109	Global burden of transmitted HIV drug resistance and HIV-exposure categories. <i>Aids</i> , 2014, 28, 2751-2762.	1.0	75
110	Human antigen-specific CD4 ⁺ CD25 ⁺ CD134 ⁺ CD39 ⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses. <i>European Journal of Immunology</i> , 2014, 44, 1644-1661.	1.6	58
111	Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1?. <i>Clinical and Translational Immunology</i> , 2014, 3, e19.	1.7	3
112	NKT cell depletion in humans during early HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 578-590.	1.0	34
113	HIV-specific antibody-dependent phagocytosis matures during HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 679-687.	1.0	29
114	Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy. <i>Journal of Infection</i> , 2014, 68, 344-354.	1.7	15
115	HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2014, 9, e93333.	1.1	5
116	HIV-1 DNA predicts disease progression and post-treatment virological control. <i>ELife</i> , 2014, 3, e03821.	2.8	270
117	Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. <i>Journal of Immunological Methods</i> , 2013, 394, 73-83.	0.6	22
118	miRNAs and HIV: unforeseen determinants of host-pathogen interaction. <i>Immunological Reviews</i> , 2013, 254, 265-280.	2.8	37
119	Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques. <i>Journal of Virology</i> , 2013, 87, 3760-3773.	1.5	94
120	Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. <i>Immunology</i> , 2013, 138, 116-123.	2.0	139
121	The search for an HIV cure: tackling latent infection. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 614-621.	4.6	61
122	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 207-217.	13.9	194
123	Results of External Quality Assessment for Proviral DNA Testing of HIV Tropism in the Maraviroc Switch Collaborative Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2063-2071.	1.8	8
124	The Majority of HIV Type 1 DNA in Circulating CD4 ⁺ T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4 ⁺ T Cells. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1330-1339.	0.5	18
125	Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e137.	2.3	48
126	Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to "protective" human leukocyte antigen-B alleles in HIV controllers. <i>Aids</i> , 2013, 27, 519-528.	1.0	43

#	ARTICLE	IF	CITATIONS
127	Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T Cells Using Qualitative Multiplex Single-Cell RT-PCR. <i>PLoS ONE</i> , 2013, 8, e74946.	1.1	16
128	Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency. <i>PLoS ONE</i> , 2013, 8, e77479.	1.1	17
129	Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. <i>Nucleic Acids Research</i> , 2012, 40, 1579-1595.	6.5	69
130	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion. <i>Archives of Internal Medicine</i> , 2012, 172, 1252.	4.3	102
131	Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. <i>Aids</i> , 2012, 26, 543-550.	1.0	62
132	T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals. <i>Clinical Immunology</i> , 2012, 144, 159-171.	1.4	11
133	Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA. <i>PLoS ONE</i> , 2012, 7, e31990.	1.1	15
134	Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells. <i>PLoS ONE</i> , 2012, 7, e38580.	1.1	22
135	A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays. <i>Tuberculosis</i> , 2012, 92, 321-327.	0.8	25
136	A novel assay for detection of hepatitis C virus-specific effector CD4+ T cells via co-expression of CD25 and CD134. <i>Journal of Immunological Methods</i> , 2012, 375, 148-158.	0.6	29
137	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011, 117, 5142-5151.	0.6	140
138	Chromatin-Associated Protein Kinase C- δ , Regulates an Inducible Gene Expression Program and MicroRNAs in Human T Lymphocytes. <i>Molecular Cell</i> , 2011, 41, 704-719.	4.5	59
139	Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. <i>Aids</i> , 2011, 25, 2069-2078.	1.0	69
140	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. <i>RNA Biology</i> , 2011, 8, 1035-1046.	1.5	45
141	Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1532-1540.	1.9	54
142	A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4+and CCR5+CD8+T Cell Numbers in Chronic HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 653-661.	0.5	14
143	Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" Fc γ R1a genotype. <i>Aids</i> , 2010, 24, 1983-1990.	1.0	37
144	An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. <i>Hum Vaccin</i> , 2010, 6, 835-840.	2.4	23

#	ARTICLE	IF	CITATIONS
145	High Viral Fitness during Acute HIV-1 Infection. PLoS ONE, 2010, 5, e12631.	1.1	12
146	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). Journal of Immunology, 2009, 183, 2827-2836.	0.4	153
147	A culture amplified multi-parametric intracellular cytokine assay (CAMP-ICC) for enhanced detection of antigen specific T-cell responses. Journal of Immunological Methods, 2009, 345, 1-16.	0.6	18
148	Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes and Infection, 2009, 11, 500-508.	1.0	73
149	Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection?. Blood, 2009, 113, 5029-5030.	0.6	22
150	Transcriptional Regulation by Promoter Targeted RNAs. Current Topics in Medicinal Chemistry, 2009, 9, 1079-1087.	1.0	33
151	Regulatory T cells in HIV infection: Who's suppressing what?. Current Infectious Disease Reports, 2008, 10, 252-258.	1.3	11
152	Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. Journal of Medical Primatology, 2008, 37, 69-78.	0.3	12
153	TCR β -Chain Sharing in Human CD8+ T Cell Responses to Cytomegalovirus and EBV. Journal of Immunology, 2008, 181, 7853-7862.	0.4	124
154	Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 140-147.	0.9	38
155	Closed Chromatin Architecture Is Induced by an RNA Duplex Targeting the HIV-1 Promoter Region. Journal of Biological Chemistry, 2008, 283, 23353-23363.	1.6	95
156	Promoter-targeted siRNAs Induce Gene Silencing of Simian Immunodeficiency Virus (SIV) Infection In Vitro. Molecular Therapy, 2008, 16, 565-570.	3.7	44
157	Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sexual Health, 2008, 5, 141.	0.4	26
158	Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 140-47.	0.9	31
159	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2007, 81, 12382-12393.	1.5	299
160	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids, 2007, 21, 2315-2321.	1.0	172
161	Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood. Journal of Immunological Methods, 2007, 326, 127-138.	0.6	7
162	Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. Journal of Experimental Medicine, 2006, 203, 1693-1700.	4.2	1,354

#	ARTICLE	IF	CITATIONS
163	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <i>Aids</i> , 2006, 20, 294-297.	1.0	58
164	Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. <i>Current HIV/AIDS Reports</i> , 2006, 3, 5-12.	1.1	22
165	The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 192-202.	0.9	26
166	A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. <i>PLOS Clinical Trials</i> , 2006, 1, e18.	3.5	26
167	CD127 + CCR5 + CD38 +++ CD4 + Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2 + Memory CD4 + T Cells. <i>Journal of Virology</i> , 2006, 80, 10151-10161.	1.5	47
168	Increased Plasma Interleukin-7 Level Correlates with Decreased CD127 and Increased CD132 Extracellular Expression on T Cell Subsets in Patients with HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2006, 193, 505-514.	1.9	108
169	Infection of CD127 + (Interleukin-7 Receptor +) CD4 + Cells and Overexpression of CTLA-4 Are Linked to Loss of Antigen-Specific CD4 T Cells during Primary Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2006, 80, 10162-10172.	1.5	84
170	Early proliferation of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection. <i>Blood</i> , 2005, 106, 1660-1667.	0.6	77
171	Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. <i>Journal of Rnai and Gene Silencing</i> , 2005, 1, 66-78.	1.2	76
172	Methodological Considerations in Human Studies of Gene Expression in HIV-Associated Lipodystrophy. <i>Antiviral Therapy</i> , 2005, 10, 101-108.	0.6	4
173	Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. <i>Blood</i> , 2004, 103, 2238-2247.	0.6	160
174	First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. <i>Virology</i> , 2003, 312, 135-150.	1.1	63
175	Rates of transmission of antiretroviral drug resistant strains of HIV-1. <i>Journal of Clinical Virology</i> , 2003, 26, 153-161.	1.6	55
176	Polyclonal Proliferation and Apoptosis of CCR5+T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection: Regulation by Interleukin (IL)-2, IL-15, and Bcl-2. <i>Journal of Infectious Diseases</i> , 2003, 187, 1735-1747.	1.9	63
177	No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection. <i>Aids</i> , 2003, 17, 264-267.	1.0	32
178	Characterization of CD4+ CTLs Ex Vivo. <i>Journal of Immunology</i> , 2002, 168, 5954-5958.	0.4	491
179	Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+T cells in peripheral blood mononuclear cells. <i>European Journal of Immunology</i> , 2002, 32, 3366-3375.	1.6	23
180	Comprehensive Analyses of a Unique HIV-1-Infected Nonprogressor Reveal a Complex Association of Immunobiological Mechanisms in the Context of Replication-Incompetent Infection. <i>Virology</i> , 2002, 304, 246-264.	1.1	41

#	ARTICLE	IF	CITATIONS
181	Relative Significance of Different Pathways of Immune Reconstitution in HIV Type 1 Infection as Estimated by Mathematical Modeling. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 147-159.	0.5	20
182	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27â€“Restricted Cytotoxic T Lymphocyte Responses. <i>Journal of Experimental Medicine</i> , 2001, 193, 375-386.	4.2	424
183	Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. <i>Aids</i> , 2000, 14, 2643-2651.	1.0	88
184	Cytotoxic T Lymphocyte Responses to Human Immunodeficiency Virus: Control and Escape. <i>Stem Cells</i> , 2000, 18, 230-244.	1.4	77
185	Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific. <i>Journal of Experimental Medicine</i> , 1998, 188, 785-790.	4.2	153
186	Mechanisms for Controlling HIV-1 Infection: A Gene Therapy Approach. , 0, , .		3